Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study

Ali Taher; Mohsen S. Elalfy; Kusai Al Zir; Shahina Daar; Abdullah Al Jefri; Dany Habr; Ulrike Kriemler-Krahn; Bernard Roubert; Amal El-Beshlawy

doi:10.1111/j.1600-0609.2011.01661.x

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study

Ali Taher, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Bernard Roubert, Amal El-Beshlawy

Haematology

Research output: Contribution to journal › Article

6 Citations (Scopus)

Abstract

This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P

Original language	English
Pages (from-to)	349-354
Number of pages	6
Journal	European Journal of Haematology
Volume	87
Issue number	4
DOIs	https://doi.org/10.1111/j.1600-0609.2011.01661.x
Publication status	Published - Oct 2011

Fingerprint

Keywords

β-thalassaemia
Deferasirox
Efficacy
Iron chelation therapy
Iron overload

ASJC Scopus subject areas

Hematology

Cite this

Taher, A., Elalfy, M. S., Al Zir, K., Daar, S., Al Jefri, A., Habr, D., ... El-Beshlawy, A. (2011). Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study. European Journal of Haematology, 87(4), 349-354. https://doi.org/10.1111/j.1600-0609.2011.01661.x

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia : Results from the ESCALATOR study. / Taher, Ali; Elalfy, Mohsen S.; Al Zir, Kusai; Daar, Shahina; Al Jefri, Abdullah; Habr, Dany; Kriemler-Krahn, Ulrike; Roubert, Bernard; El-Beshlawy, Amal.

In: European Journal of Haematology, Vol. 87, No. 4, 10.2011, p. 349-354.

Research output: Contribution to journal › Article

Taher, A, Elalfy, MS, Al Zir, K, Daar, S, Al Jefri, A, Habr, D, Kriemler-Krahn, U, Roubert, B & El-Beshlawy, A 2011, 'Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study', European Journal of Haematology, vol. 87, no. 4, pp. 349-354. https://doi.org/10.1111/j.1600-0609.2011.01661.x

Taher, Ali ; Elalfy, Mohsen S. ; Al Zir, Kusai ; Daar, Shahina ; Al Jefri, Abdullah ; Habr, Dany ; Kriemler-Krahn, Ulrike ; Roubert, Bernard ; El-Beshlawy, Amal. / Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia : Results from the ESCALATOR study. In: European Journal of Haematology. 2011 ; Vol. 87, No. 4. pp. 349-354.

@article{8b02e0f0bd9a49acbcab074dc2e2868b,

title = "Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study",

abstract = "This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P",

keywords = "β-thalassaemia, Deferasirox, Efficacy, Iron chelation therapy, Iron overload",

author = "Ali Taher and Elalfy, {Mohsen S.} and {Al Zir}, Kusai and Shahina Daar and {Al Jefri}, Abdullah and Dany Habr and Ulrike Kriemler-Krahn and Bernard Roubert and Amal El-Beshlawy",

year = "2011",

month = "10",

doi = "10.1111/j.1600-0609.2011.01661.x",

language = "English",

volume = "87",

pages = "349--354",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia

T2 - Results from the ESCALATOR study

AU - Taher, Ali

AU - Elalfy, Mohsen S.

AU - Al Zir, Kusai

AU - Daar, Shahina

AU - Al Jefri, Abdullah

AU - Habr, Dany

AU - Kriemler-Krahn, Ulrike

AU - Roubert, Bernard

AU - El-Beshlawy, Amal

PY - 2011/10

Y1 - 2011/10

N2 - This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P

AB - This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P

KW - β-thalassaemia

KW - Deferasirox

KW - Efficacy

KW - Iron chelation therapy

KW - Iron overload

UR - http://www.scopus.com/inward/record.url?scp=80053284827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053284827&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2011.01661.x

DO - 10.1111/j.1600-0609.2011.01661.x

M3 - Article

C2 - 21668501

AN - SCOPUS:80053284827

VL - 87

SP - 349

EP - 354

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -

Access to Document

10.1111/j.1600-0609.2011.01661.x